- Home
- Posts
- 🍄 Trip Sheet: Compass Pathways (CMPS) eyes FDA approval path after positive Phase 3 psilocybin data
🍄 Trip Sheet: Compass Pathways (CMPS) eyes FDA approval path after positive Phase 3 psilocybin data
CPO Dr. Guy Levine tells The Fly the company is already designing a late-stage PTSD trial while preparing providers for COMP360 rollout.
Jul 10, 2025
Street Sheet Research Members Only
This content is for Street Sheet Research subscribers. Click the button below to join. You'll receive our weekly research report, monthly deep-dives, and instant access to The Street Feed.
JOIN STREET SHEET RESEARCH FOR JUST $99